<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33394200</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-131X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medical oncology (Northwood, London, England)</Title>
          <ISOAbbreviation>Med Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Steps in metastasis: an updated review.</ArticleTitle>
        <Pagination>
          <StartPage>3</StartPage>
          <MedlinePgn>3</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12032-020-01447-w</ELocationID>
        <Abstract>
          <AbstractText>Metastasis is the most complex and deadly event. Tumor-stromal interface is a place where invasion of tumor cells in the form of single-cell or collective migration occurs, with the latter being less common but more efficient. Initiation of metastasis relies on the tumor cell cross-talking with stromal cells and taking an epithelial-mesenchymal transition (EMT) in single cells, and a hybrid EMT in collective migratory cells. Stromal cross-talking along with an abnormal leaky vasculature facilitate intravasation of tumor cells, here the cells are called circulating tumor cells (CTCs). Tumor cells isolated from the primary tumor exploit several mechanisms to maintain their survival including rewiring metabolic demands to use sources available within the new environments, avoiding anoikis cell death when cells are detached from extracellular matrix (ECM), adopting flow mechanic by acquiring platelet shielding and immunosuppression by negating the activity of suppressor immune cells, such as natural killer (NK) cells. CTCs will adhere to the interstituim of the secondary organ/s, within which the newly arrived disseminative tumor cells (DTCs) undergo either dormancy or proliferation. Metastatic outgrowth is under the influence of several factors, such as the activity of macrophages, impaired autophagy and secondary site inflammatory events. Metastasis can be targeted by multiple ways, such as repressing the promoters of pre-metastatic niche (PMN) formation, suppressing environmental contributors, such as hypoxia, oxidative and metabolic stressors, and targeting signaling and cell types that take major contribution to the whole process. These strategies can be used in adjuvant with other therapeutics, such as immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Majidpoor</LastName>
            <ForeName>Jamal</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mortezaee</LastName>
            <ForeName>Keywan</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-2004-3465</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. Keywan987@yahoo.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Keywan987@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Med Oncol</MedlineTA>
        <NlmUniqueID>9435512</NlmUniqueID>
        <ISSNLinking>1357-0560</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018523" MajorTopicYN="N">Tropism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">C-X-C chemokine (CXC)</Keyword>
        <Keyword MajorTopicYN="N">Cancer-associated fibroblast (CAF)</Keyword>
        <Keyword MajorTopicYN="N">Circulating tumor cell (CTC)</Keyword>
        <Keyword MajorTopicYN="N">Epithelial-mesenchymal transition (EMT)</Keyword>
        <Keyword MajorTopicYN="N">Invasion</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">Platelet</Keyword>
        <Keyword MajorTopicYN="N">Survival</Keyword>
        <Keyword MajorTopicYN="N">Transforming growth factor (TGF)</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment (TME)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33394200</ArticleId>
        <ArticleId IdType="doi">10.1007/s12032-020-01447-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s12032-020-01447-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graham TA, Shibata D. Navigating the path to distant metastasis. Nat Genet. 2020;52(7):642–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32632324</ArticleId>
            <ArticleId IdType="pmc">7747770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aytes A, et al. NSD2 is a conserved driver of metastatic prostate cancer progression. Nat Commun. 2018;9(1):1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu Z, Curtis C. Looking backward in time to define the chronology of metastasis. Nat Commun. 2020;11(1):1–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Mortezaee K. CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis. Life Sci. 2020:117534.</Citation>
        </Reference>
        <Reference>
          <Citation>Müller A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11242036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Y, Du Y. Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review. Int J Surg. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>López-Soto A, et al. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28810142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28187288</ArticleId>
            <ArticleId IdType="pmc">5308465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul CD, Mistriotis P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer. 2017;17(2):131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27909339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YH, et al. Senescent tumor cells lead the collective invasion in thyroid cancer. Nat Commun. 2017;8:15208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28489070</ArticleId>
            <ArticleId IdType="pmc">5436223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012;12(10):699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23001349</ArticleId>
            <ArticleId IdType="pmc">3969886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laudato, S., A. Aparicio, and F.G. Giancotti, Clonal evolution and epithelial plasticity in the emergence of AR-independent prostate carcinoma. Trends in cancer, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Castaño Z, et al. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol. 2018;20(9):1084–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30154549</ArticleId>
            <ArticleId IdType="pmc">6511979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell. 2020;37(1):8–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31935374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo HC, et al. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat Cancer. 2020:1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32(3):282–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28898694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanaban V, et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573(7774):439–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31485072</ArticleId>
            <ArticleId IdType="pmc">7365572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiyoshi K, et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine. 2020;57:102860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32652320</ArticleId>
            <ArticleId IdType="pmc">7347996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VanderVorst K, et al. Wnt/PCP signaling contribution to carcinoma collective cell migration and metastasis. Cancer Res. 2019;79(8):1719–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30952630</ArticleId>
            <ArticleId IdType="pmc">6467734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing. Nat Commun. 2020;11(1):1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26875870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinbichler, T.B., et al. The role of exosomes in cancer metastasis. in Seminars in cancer biology. 2017. Elsevier.</Citation>
        </Reference>
        <Reference>
          <Citation>Najafi M, Mortezaee K, Majidpoor J. Stromal reprogramming: a target for tumor therapy. Life Sci. 2019;239:117049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31730862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30594349</ArticleId>
            <ArticleId IdType="pmc">30594349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck, R., S.J. Turley, and R.J. Akhurst, TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol, 2020: p. 1–26.</Citation>
        </Reference>
        <Reference>
          <Citation>Tong L, et al. Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis. Cell Death Differ. 2020;27(6):1795–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31767934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fares J, et al. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):1–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31430455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Najafi M, Mortezaee K, Ahadi R. Cancer stem cell (a) symmetry &amp; plasticity: tumorigenesis and therapy relevance. Life Sci. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>Labernadie A, et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol. 2017;19(3):224–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28218910</ArticleId>
            <ArticleId IdType="pmc">5831988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glentis A, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 2017;8(1):1–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson RL, et al. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16(3):185–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30514977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukumura D, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29508855</ArticleId>
            <ArticleId IdType="pmc">5921900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin F, et al. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol Cancer Res. 2012;10(8):1021–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22767589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donato C, et al. Hypoxia triggers the Intravasation of clustered circulating tumor cells. Cell Rep. 2020;32(10):108105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32905777</ArticleId>
            <ArticleId IdType="pmc">7487783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ breast cancer. 2016;2(1):1–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30361552</ArticleId>
            <ArticleId IdType="pmc">30361552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kai F, Laklai H, Weaver VM. Force matters: biomechanical regulation of cell invasion and migration in disease. Trends Cell Biol. 2016;26(7):486–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27056543</ArticleId>
            <ArticleId IdType="pmc">4970516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28241846</ArticleId>
            <ArticleId IdType="pmc">5329931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29065107</ArticleId>
            <ArticleId IdType="pmc">5729447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45(1):229–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28202677</ArticleId>
            <ArticleId IdType="pmc">5371349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chronopoulos A, et al. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun. 2016;7(1):1–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeltz, C., et al. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. in Seminars in cancer biology. 2020. Elsevier.</Citation>
        </Reference>
        <Reference>
          <Citation>Farhood B, Najafi M, Mortezaee K. Cancer-associated fibroblasts: secretions, interactions, and therapy. J Cell Biochem. 2019;120(3):2791–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30260049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30470818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su SC, et al. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1):e12370.</Citation>
        </Reference>
        <Reference>
          <Citation>García-Jiménez C, Goding CR. Starvation and pseudo-starvation as drivers of cancer metastasis through translation reprogramming. Cell Metab. 2019;29(2):254–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30581118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang, Q., et al., Mutant p53 on the Path to Metastasis. Trends in Cancer, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim Y-N, et al. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J cell Biol. 2012;2012</Citation>
        </Reference>
        <Reference>
          <Citation>De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol. 2011;8(7):393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21629216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26807644</ArticleId>
            <ArticleId IdType="pmc">4728678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis RT, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22(3):310–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32144411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019;20(7):436–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30976106</ArticleId>
            <ArticleId IdType="pmc">6592760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi N, et al. Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance. Cancer Cell. 2018;33(6):985–1003. e7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29805077</ArticleId>
            <ArticleId IdType="pmc">6100788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheeler LJ, et al. Multi-omic approaches identify metabolic and autophagy regulators important in ovarian cancer dissemination. iScience. 2019;19:474–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31437751</ArticleId>
            <ArticleId IdType="pmc">6710300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Najafi M, Ahmadi A, Mortezaee K. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review. Cell Biol Int. 2019;43(11):1206–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31136035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K. Human hepatocellular carcinoma: protection by melatonin. J Cell Physiol. 2018;233(10):6486–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29672851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren W, et al. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis. Swiss Med Wkly. 2013;143(3536)</Citation>
        </Reference>
        <Reference>
          <Citation>Coronel J, et al. Weekly topotecan as second-or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol. 2009;26(2):210–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19016011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wadler S, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: eastern cooperative oncology group study E3E93. J Clin Oncol. 2003;21(11):2110–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12775736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, et al. Zinc finger protein 367 promotes metastasis by inhibiting the hippo pathway in breast cancer. Oncogene. 2020;39(12):2568–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31988454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka K, et al. Statin suppresses hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27773750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maille E, et al. MST1/hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial. Br J Cancer. 2019;120(4):387–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30739911</ArticleId>
            <ArticleId IdType="pmc">6461894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higashi T, et al. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. Med Oncol. 2016;33(11):123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27734263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Follain G, et al. Fluids and their mechanics in tumour transit: shaping metastasis. Nat Rev Cancer. 2019:1–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Marcolino E, et al. Blood platelets stimulate cancer extravasation through TGFβ-mediated downregulation of PRH/HHEX. Oncogenesis. 2020;9(2):1–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaertner F, Massberg S. Patrolling the vascular borders: platelets in immunity to infection and cancer. Nat Rev Immunol. 2019:1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Owen KL, et al. Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Rep. 2020:e50162.</Citation>
        </Reference>
        <Reference>
          <Citation>Guan X, et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. 2019;39(1):1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z-L, et al. Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC. Cancer Biol Ther. 2019;20(4):505–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30359544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, et al. Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer. J Cell Biochem. 2019;120(4):4935–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30260024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen EY, et al. A phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer. Am J Clin Oncol. 2018;41(12):1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29782360</ArticleId>
            <ArticleId IdType="pmc">6240505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6):884–901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20627072</ArticleId>
            <ArticleId IdType="pmc">2905377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, et al. Role of cancer emboli as a metastatic core on the growth of brain metastasis in patients with non-small cell lung cancer. J Neurointensive Care. 2020;</Citation>
        </Reference>
        <Reference>
          <Citation>Silvestre-Roig C, et al. Neutrophil diversity in health and disease. Trends Immunol. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26377897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montagner M, et al. Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nat Cell Biol. 2020:1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Roberts S, Agrawal N. Temporal analysis of CTC-endothelium interactions during early metastasis. in 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC). 2015. IEEE.</Citation>
        </Reference>
        <Reference>
          <Citation>Bersini S, et al. A combined microfluidic-transcriptomic approach to characterize the extravasation potential of cancer cells. Oncotarget. 2018;9(90):36110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30546831</ArticleId>
            <ArticleId IdType="pmc">6281425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, King MR. Adhesion receptors as therapeutic targets for circulating tumor cells. Front Oncol. 2012;2:79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22837985</ArticleId>
            <ArticleId IdType="pmc">3402858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbazán J, et al. Liver metastasis is facilitated by the adherence of circulating tumor cells to vascular fibronectin deposits. Cancer Res. 2017;77(13):3431–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28536280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osmani N, et al. Metastatic tumor cells exploit their adhesion repertoire to counteract shear forces during intravascular arrest. Cell Rep. 2019;28(10):2491–500. e5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31484062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osmani N, et al, Intravascular arrest of circulating tumor cells is a two-step process exploiting their adhesion repertoire. Available at SSRN 3272239, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Hynes W, et al. Examining metastatic behavior within 3D bioprinted vasculature for the validation of a 3D computational flow model. Sci Adv. 2020;6(35):eabb3308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32923637</ArticleId>
            <ArticleId IdType="pmc">7449690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkretsi V, Stylianopoulos T. Cell adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis. Front Oncol. 2018;8:145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29780748</ArticleId>
            <ArticleId IdType="pmc">5945811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leong HS, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014;8(5):1558–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25176655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KC, et al. Invadopodia are chemosensing protrusions that guide cancer cell extravasation to promote brain tropism in metastasis. Oncogene. 2019;38(19):3598–615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30651600</ArticleId>
            <ArticleId IdType="pmc">6756237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneyama MS, et al. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. Eur J Cell Biol. 2014;93(4):157–69.</Citation>
        </Reference>
        <Reference>
          <Citation>Diepenbruck M, Christofori G. Epithelial–mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27371787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Achrol AS, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):1–26.</Citation>
        </Reference>
        <Reference>
          <Citation>Guereño M, et al. Glypican-3 (GPC3) inhibits metastasis development promoting dormancy in breast cancer cells by p38 MAPK pathway activation. Eur J Cell Biol. 2020;99(6):151096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32800275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gau DM, et al. Abstract LB-043: MRTF| Profilin is an important signaling axis for metastatic outgrowth of triple negative breast cancer cells. 2019, AACR.</Citation>
        </Reference>
        <Reference>
          <Citation>Flynn ALB, et al. Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019;10(1):1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodrigues G, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21(11):1403–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31685984</ArticleId>
            <ArticleId IdType="pmc">7354005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma R-Y, et al. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J Exp Med. 2020;217(11)</Citation>
        </Reference>
        <Reference>
          <Citation>Farhood B, et al. Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy. J Cell Biochem. 2019;120(1):71–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30203529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K. Immune escape: a critical hallmark in solid tumors. Life Sci. 2020:118110.</Citation>
        </Reference>
        <Reference>
          <Citation>Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27055731</ArticleId>
            <ArticleId IdType="pmc">5407285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez-Roca C, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30(8):1381–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Marsh T, et al. Autophagic degradation of NBR1 restricts metastatic outgrowth during mammary tumor progression. Dev Cell. 2020;52(5):591–604. e6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32084360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malhotra J, et al. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Treat Res Commun. 2019;21:100158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31521049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karasic TB, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(7):993–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31120501</ArticleId>
            <ArticleId IdType="pmc">6547080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. NADPH oxidase as a target for modulation of radiation response; implications to carcinogenesis and radiotherapy. Curr Mol Pharmacol. 2019;12(1):50–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30318012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nandi P, et al. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer. 2017;17(1):1–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Du C, et al. Tumour-derived exosomal miR-3473b promotes lung tumour cell intrapulmonary colonization by activating the nuclear factor-κB of local fibroblasts. J Cell Mol Med. 2020;</Citation>
        </Reference>
        <Reference>
          <Citation>Najafi M, et al. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 2020;146(1):19–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31734836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. NF-κB targeting for overcoming tumor resistance and normal tissues toxicity. J Cell Physiol. 2019;234(10):17187–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30912132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: a review. Cell Biochem Funct. 2018;36(6):292–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30028028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al. Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases. Sci Transl Med. 2020;12(545)</Citation>
        </Reference>
        <Reference>
          <Citation>Yang L, et al. Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization. Cancer Res. 2020;</Citation>
        </Reference>
        <Reference>
          <Citation>Pein M, et al. CXCR3-expressing metastasis-initiating cells induce and exploit a fibroblast niche in the lungs to fuel metastatic colonization. bioRxiv, 2019: p. 546952.</Citation>
        </Reference>
        <Reference>
          <Citation>Miarka L, et al. The hepatic microenvironment and TRAIL-R2 impact outgrowth of liver metastases in pancreatic Cancer after surgical resection. Cancers. 2019;11(6):745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">6627672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X, et al. SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis. Nat Commun. 2017;8(1):1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Su W, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell. 2019;36(2):139–55. e10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31327655</ArticleId>
            <ArticleId IdType="pmc">7210785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He B, et al. Remodeling of metastatic vasculature reduces lung colonization and sensitizes overt metastases to immunotherapy. Cell Rep. 2020;30(3):714–24. e5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31968248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo C-L, et al. Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett. 2020;474:138–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31987921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K. Hypoxia induces core-to-edge transition of progressive tumoral cells: a critical review on differential yet corroborative roles for HIF-1α and HIF-2α. Life Sci. 2020;242:117145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31816327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. Redox interactions and genotoxicity of metal-based nanoparticles: a comprehensive review. Chem Biol Interact. 2019:108814.</Citation>
        </Reference>
        <Reference>
          <Citation>Najafi M, et al. Adjuvant chemotherapy with melatonin for targeting human cancers: a review. J Cell Physiol. 2019;234(3):2356–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30192001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farhood B, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol. 2019;21(3):268–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30136132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: an updated review. Life Sci. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. Boosting immune system against cancer by melatonin: a mechanistic viewpoint. Life Sci. 2019:116960.</Citation>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. Resveratrol as an adjuvant for normal tissues protection and tumor sensitization. Curr Cancer Drug Targets. 2019;</Citation>
        </Reference>
        <Reference>
          <Citation>Mortezaee K, et al. Metformin as a radiation modifier; implications to normal tissue protection and tumor sensitization. Curr Clin Pharmacol. 2019;14(1):41–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30360725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farhood B, et al. Curcumin as an anti-inflammatory agent: implications to radiotherapy and chemotherapy. J Cell Physiol. 2019;234(5):5728–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji Q, et al. Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation. Nat Commun. 2020;11(1):1–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin B, et al. CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. Oncogene. 2020:1–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Bajaj R, et al. IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. Oncogene. 2020:1–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Ko C-J, et al. Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis. Oncogene. 2020:1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng Y, et al. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 2020;5(1):1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Z, et al. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism. Signal Transduct Target Ther. 2020;5(1):1–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu X, et al. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Commun Biol. 2020;3(1):1–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou Z, et al. VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling. Cancer Lett. 2020;473:62–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31904479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Z, et al. Tenascin-C increases lung metastasis by impacting blood vessel invasions. Matrix Biol. 2019;83:26–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31288084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seachrist DD, et al. The transcriptional repressor BCL11A promotes breast cancer metastasis. J Biol Chem. 2020;295(33):11707–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32576660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis. Clin Cancer Res. 2020;26(6):1460–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31857432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sjöberg E, et al. A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer. Clin Cancer Res. 2019;25(12):3702–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30850359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, et al. The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2. Cell Death Dis. 2019;10(8):1–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Hendrikx S, et al. Endothelial calcineurin signaling restrains metastatic outgrowth by regulating Bmp2. Cell Rep. 2019;26(5):1227–41. e6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30699351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howe EN, et al. Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth. Nat Commun. 2020;11(1):1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Sinha S, et al. Abstract A50: IMPACT inhibits metastatic outgrowth in pancreatic cancer by restraining GCN1-ATF4 signaling. 2019, AACR.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoj JP, Mayro B, Pendergast AM. A TAZ-AXL-ABL2 feed-forward signaling axis promotes lung adenocarcinoma brain metastasis. Cell Rep. 2019;29(11):3421–34. e8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31825826</ArticleId>
            <ArticleId IdType="pmc">7254883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urosevic J, et al. ERK1/2 signaling induces upregulation of ANGPT2 and CXCR4 to mediate liver metastasis in colon cancer. Cancer Res. 2020;</Citation>
        </Reference>
        <Reference>
          <Citation>Tulotta C, et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 2019;25(9):2769–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30670488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi N, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and nucleotide biosynthesis under hypoxia. bioRxiv, 2019: p. 833186.</Citation>
        </Reference>
        <Reference>
          <Citation>McKernan CM, Pendergast AM. Abstract P3–03-04: Role of ABL kinase signaling in metastatic breast cancer colonization of the brain. 2020, AACR.</Citation>
        </Reference>
        <Reference>
          <Citation>Li L, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38(35):6241–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31312026</ArticleId>
            <ArticleId IdType="pmc">6715537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polireddy K, et al. High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: mechanisms and a phase I/IIa study. Sci Rep. 2017;7(1):1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodón J, et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Investig New Drugs. 2015;33(2):357–70.</Citation>
        </Reference>
        <Reference>
          <Citation>Kashiwagi S, et al. Mesenchymal–epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer. Anticancer Res. 2018;38(1):401–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29277801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, et al. Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial–mesenchymal transition inhibition. Int J Nanomedicine. 2017;12:3509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28496326</ArticleId>
            <ArticleId IdType="pmc">5422535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorensen AG, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72(2):402–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22127927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas RP, et al. Macrophage exclusion after radiation therapy (MERT): a first in human phase I/II trial using a CXCR4 inhibitor in glioblastoma. Clin Cancer Res. 2019;25(23):6948–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31537527</ArticleId>
            <ArticleId IdType="pmc">6891194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah MA, et al. Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study. Clin Cancer Res. 2018;24(16):3829–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29691300</ArticleId>
            <ArticleId IdType="pmc">7496223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannelli G, et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One. 2020;15(3):e0222259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32210440</ArticleId>
            <ArticleId IdType="pmc">7094874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelley R, et al. A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10(7)</Citation>
        </Reference>
        <Reference>
          <Citation>Melisi D, et al. TGFβ receptor inhibitor galunisertib is linked to inflammation-and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2019;83(5):975–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30887178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan RJ, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29247021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, et al. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. J Hematol Oncol. 2019;12(1):9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30642372</ArticleId>
            <ArticleId IdType="pmc">6332596</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
